secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000929638-23-003066
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene finalizes employment agreements with CEO, COO, CSO, CTO; salaries $450k-$590k
--------------------------------------------------------------------------------

- CEO Jason Hanson: $590k base, 55% annual bonus target, 12-month severance non-CIC, 18-month CIC.
- COO Alex Nichols: $475k base, 40% bonus target, 12-month severance non-CIC, 12-month CIC.
- CSO James Sullivan: $485k base, 40% bonus target, 12-month severance non-CIC, 12-month CIC.
- CTO Anthony Cheung: $450k base, 40% bonus target, 18-month severance (non-CIC and CIC).
- All agreements effective Nov 1, 2023; cover restrictive covenants, equity acceleration, and COBRA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000092963823003066/0000929638-23-003066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000092963823003066/a8k.htm
  HTML page:      https://secwatch.observer/filing/0000929638-23-003066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer